ATE529116T1 - Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect) - Google Patents

Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect)

Info

Publication number
ATE529116T1
ATE529116T1 AT03726554T AT03726554T ATE529116T1 AT E529116 T1 ATE529116 T1 AT E529116T1 AT 03726554 T AT03726554 T AT 03726554T AT 03726554 T AT03726554 T AT 03726554T AT E529116 T1 ATE529116 T1 AT E529116T1
Authority
AT
Austria
Prior art keywords
ect
therapeutic response
enhancement
electroconvulsive therapy
electroconvulsive
Prior art date
Application number
AT03726554T
Other languages
English (en)
Inventor
Alan Schatzberg
Joseph Belanoff
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Application granted granted Critical
Publication of ATE529116T1 publication Critical patent/ATE529116T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Electrotherapy Devices (AREA)
AT03726554T 2002-04-29 2003-04-28 Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect) ATE529116T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37681402P 2002-04-29 2002-04-29
US10/411,503 US7326697B2 (en) 2002-04-29 2003-04-08 Methods for increasing the therapeutic response to electroconvulsive therapy
PCT/US2003/013498 WO2003092790A2 (en) 2002-04-29 2003-04-28 Methods for increasing the therapeutic response to electroconvulsive therapy ('ect')

Publications (1)

Publication Number Publication Date
ATE529116T1 true ATE529116T1 (de) 2011-11-15

Family

ID=29406770

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03726554T ATE529116T1 (de) 2002-04-29 2003-04-28 Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect)

Country Status (16)

Country Link
US (1) US7326697B2 (de)
EP (1) EP1499321B1 (de)
JP (2) JP2005526843A (de)
KR (1) KR100970834B1 (de)
CN (1) CN100438875C (de)
AT (1) ATE529116T1 (de)
AU (1) AU2003228783B2 (de)
CA (1) CA2483855C (de)
ES (1) ES2375356T3 (de)
HK (1) HK1068783A1 (de)
IL (2) IL164793A0 (de)
MX (1) MXPA04010705A (de)
NO (1) NO335006B1 (de)
NZ (1) NZ536248A (de)
PT (1) PT1499321E (de)
WO (1) WO2003092790A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
US20110125203A1 (en) * 2009-03-20 2011-05-26 ElectroCore, LLC. Magnetic Stimulation Devices and Methods of Therapy
US8812112B2 (en) * 2005-11-10 2014-08-19 ElectroCore, LLC Electrical treatment of bronchial constriction
US9037247B2 (en) 2005-11-10 2015-05-19 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US8041428B2 (en) 2006-02-10 2011-10-18 Electrocore Llc Electrical stimulation treatment of hypotension
CN101674862A (zh) * 2005-11-10 2010-03-17 电子核心公司 支气管收缩的电刺激治疗
AU2006337679A1 (en) * 2006-02-10 2007-08-16 Electrocore, Inc. Methods and apparatus for treating anaphylaxis using electrical modulation
WO2007094828A2 (en) * 2006-02-10 2007-08-23 Electrocore, Inc. Electrical stimulation treatment of hypotension
US20100241188A1 (en) * 2009-03-20 2010-09-23 Electrocore, Inc. Percutaneous Electrical Treatment Of Tissue
EP1987814A1 (de) * 2007-04-30 2008-11-05 Exelgyn Pharmazeutische Mifepristonzusammensetzungen und Herstellungsverfahren dafür
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
ES2398052T5 (es) 2008-05-09 2021-10-25 Nuvaira Inc Sistemas para tratar un árbol bronquial
EP2926757B1 (de) 2009-10-27 2023-01-25 Nuvaira, Inc. Freisetzungsvorrichtungen mit kühlbaren energieemissionsanordnungen
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
CN106618731B (zh) 2009-11-11 2020-08-07 努瓦拉公司 用于处理组织和控制狭窄的系统、装置和方法
US20120245552A1 (en) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination Therapy
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296206A (en) 1980-04-30 1981-10-20 United States Of America Irreversible anti-glucocorticoids
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US4873981A (en) 1988-10-14 1989-10-17 Somatics, Inc. Electroconvulsive therapy apparatus and method for automatic monitoring of patient seizures
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
PT1023074E (pt) 1997-10-06 2006-12-29 Trustees Leland Stanford Junio Métodos para tratamento de psicose associada a disfunção relacionada com glucocorticóides
AU756818B2 (en) 1998-05-15 2003-01-23 Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid receptor antagonists for the treatment of dementia
CA2510133C (en) * 2002-12-18 2012-06-26 Koninklijke Philips Electronics N.V. System for removably joining a driven member to a driven member with workpiece

Also Published As

Publication number Publication date
IL164793A0 (en) 2005-12-18
US7326697B2 (en) 2008-02-05
NO20045232L (no) 2005-01-26
EP1499321A2 (de) 2005-01-26
AU2003228783A1 (en) 2003-11-17
MXPA04010705A (es) 2005-02-17
IL164793A (en) 2012-02-29
WO2003092790A3 (en) 2003-12-11
KR20040105247A (ko) 2004-12-14
ES2375356T3 (es) 2012-02-29
EP1499321B1 (de) 2011-10-19
PT1499321E (pt) 2012-02-01
NZ536248A (en) 2007-03-30
JP2005526843A (ja) 2005-09-08
WO2003092790A2 (en) 2003-11-13
EP1499321A4 (de) 2008-09-03
CA2483855C (en) 2012-01-10
AU2003228783C1 (en) 2003-11-17
HK1068783A1 (en) 2005-05-06
JP2011116771A (ja) 2011-06-16
CN100438875C (zh) 2008-12-03
NO335006B1 (no) 2014-08-25
CA2483855A1 (en) 2003-11-13
CN1658883A (zh) 2005-08-24
KR100970834B1 (ko) 2010-07-16
AU2003228783B2 (en) 2006-11-16
US20040029849A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
ATE529116T1 (de) Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect)
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
DE69835225D1 (de) Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
EA200700097A1 (ru) Производные хиназолин-4-илпиперидина и циннолин-4-илпиперидина в качестве ингибиторов pde10 для лечения расстройств цнс
MY169308A (en) Treatment of tnf? related disorders
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
ATE450251T1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
MX2007000606A (es) Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno.
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
TW200621244A (en) Modulators of muscarinic receptors
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
NO20065297L (no) Anvendelse av GPCR54 ligander til behandling av infertilitet
TW200636242A (en) Methods of modulating the activities of α7 nicotinic acetylcholine receptor
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
NO20055309L (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
ATE279208T1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
MX2007006382A (es) Moduladores de receptores muscarinicos.
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit